mycapssa
amryt pharmaceuticals dac - octreotide acetate - акромегалия - Хипофизни и хипоталамични хормони и аналози - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
octreotide lyomark 0,1 mg/ml solution for injection
lyomark pharma gmbh - Октреотид - 0,1 mg/ml solution for injection
octreotide lyomark 0,05 mg/ml solution for injection
lyomark pharma gmbh - Октреотид - 0,05 mg/ml solution for injection
octreotide csc 500 micrograms/ml solution for injection
gp pharm, s.a. - 500 micrograms/ml solution for injection
octreotide csc 100 micrograms/ml solution for injection
gp pharm, s.a. - 100 micrograms/ml solution for injection
octreotide csc 50 micrograms/ml solution for injection
gp pharm, s.a. - 50 micrograms/ml solution for injection
octreotide lai teva 20 mg powder and solvent for prolonged - release suspension for injection
20 mg powder and solvent for prolonged - release suspension for injection
octreotide lai teva 30 mg powder and solvent for prolonged - release suspension for injection
30 mg powder and solvent for prolonged - release suspension for injection
sandostatin 100 microgram/1 ml solution for injection/infusion
novartis pharma gmbh - Октреотид - 100 microgram/1 ml solution for injection/infusion
sandostatin lar 20 mg powder and solvent for suspension for injection
novartis pharma gmbh - Октреотид - 20 mg powder and solvent for suspension for injection